EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Catastrophic health expenditures and medical impoverishment in Bangladesh: evidence from the Household Income and Expenditure Survey

Abdur Razzaque Sarker, Rasedul Islam, An Tran-Duy

BMJ Open · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Objectives Catastrophic health expenditure (CHE) and impoverishment due to out-of-pocket (OOP) expenditure are the most widely used metrics to assess financial protection in health. This study aimed to investigate the impact of OOP expenditure on CHE and impoverishment in Bangladesh and identify their determinants. Design A national cross-sectional survey. Setting We used data from the latest Household Income and Expenditure Survey 2022 in Bangladesh. Participants 14 395 households from eight administrative divisions in Bangladesh. Primary and secondary outcome measures The well-known methodology developed by Wagstaff and Doorslaer was used in this study to estimate the prevalence of CHE and the effect of OOP spending on impoverishment. We used a generalised linear model with a log link and a gam ma distribution to assess the association between the explanatory variables and annual OOP expenditure. Results The prevalence of CHE was estimated to be 17.72% (95% CI 17.71% to 17.73%) and 7.07% (95% CI 7.06% to 7.08%) using 10% and 25% of the total consumption expenditure as thresholds, respectively. Given the 40% of non-food expenditure threshold level, about 9.46% (95% CI 9.45% to 9.47%) of households faced CHE due to OOP expenditure in Bangladesh. In 2022, approximately 3.7% (95% CI 3.7% to 3.71%) of the population (6.13 million people) fell into poverty in Bangladesh. The prevalence of CHE was higher among male-headed households, larger families, households with elderly members, households with members suffering from chronic illnesses, those using hospital care and individuals in the poorest wealth quintiles. Conclusions Our study indicated that the financial burden due to OOP expenditure was substantial in Bangladesh. Findings stress the need for prepayment schemes such as national health insurance for safeguarding households against falling into poverty.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Abdur Razzaque Sarker, Rasedul Islam, An Tran-Duy
Quelle
BMJ Open
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2044-6055, 2044-6055
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Abdur Razzaque Sarker, Rasedul Islam, An Tran-Duy (2026). Catastrophic health expenditures and medical impoverishment in Bangladesh: evidence from the Household Income and Expenditure Survey. BMJ Open. https://doi.org/10.1136/bmjopen-2025-111600
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1